DDInter424 DDInter1676
Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes. More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Cobicistat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Cobicistat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Cobicistat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alprazolam
Cobicistat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pitolisant
Cobicistat {u} may lead to a major life threatening interaction when taken with {v} Methylprednisolone
Cobicistat {u} may lead to a major life threatening interaction when taken with {v} Berotralstat
Cobicistat may cause a minor interaction that can limit clinical effects when taken with Donepezil
Cobicistat may cause a minor interaction that can limit clinical effects when taken with Doravirine
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Cobicistat may lead to a major life threatening interaction when taken with Methylprednisolone
Cobicistat may lead to a major life threatening interaction when taken with Berotralstat